Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world Comparative Effectiveness of Rivaroxaban Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism (RECENT)

Next Previous
Trial Profile

Real-world Comparative Effectiveness of Rivaroxaban Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism (RECENT)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparins; Phenprocoumon
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms RECENT
  • Sponsors Bayer

Most Recent Events

  • 08 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 21 Apr 2021 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
  • 21 Apr 2021 Planned primary completion date changed from 31 Mar 2021 to 31 May 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top